Would you treat a patient with non-clear cell renal cell carcinoma with nivolumab and ipilimumab?
Any data to support this combination for non-clear cell RCC?
Answer from: Medical Oncologist at Academic Institution
Use of ipi/nivo for non-clear cell RCC would not typically be my 1st choice for systemic therapies. In CheckMate 920 (N=52), the objective response rate to ipi/nivo in treatment naive non-clear cell RCC was 19.6% with a median PFS 3.7 months. (Tykodi et al., ASCO GU 2021)In HCRN GU16-260 Cohort...
Sign in or Register to read more